EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

28 May 2012

Independent German drug major Boehringer Ingelheim and US partner  Eli Lilly (NYSE: LLY)  have received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending approval of their diabetes drug Jentadueto, which combines the DPP-4 inhibitor, linagliptin (the active ingredient in Trajenta) and metformin in a single tablet.

If approved by the European Commission, linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with type 2 diabetes who need to improve control of their blood glucose. 1 In clinical studies, linagliptin/metformin HCl demonstrated benefit to patients by offering another dosing option with effective glycemic control and a favourable side effect profile.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical